Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

IBDoc® Citation:

Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF, Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clinical Gastroenterology and Hepatology (2017) Jun 9. pii: S1542-3565(17)30712-7. DOI:10.1016/j.cgh.2017.06.007,  PMID:28606846.

Highlights from this Publication

“… we showed that the smartphone reader used by patients at home performed as good as the point-of-care Quantum Blue reader in the hospital. Additional benefits of the home test include a reduction of the burden on hospital laboratory resources and a more patient-friendly sampling technique…”

“…We found sufficient agreement between the home-used lateral flow test and the hospital-based ELISA test in the lower ranges of calprotectin to use this new test for
telemonitoring of patients with asymptomatic IBD…”

“…Calprotectin home monitoring with a smartphone fits perfectly in the current spirit of the times and is another important step towards patient-centered care…”

Health Canada License: 98903
US: Not available for Sale in the US.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone